Glucagon increases expenditure
Current weight-loss medications generally target one or two metabolic hormone pathways
Injections need to be given in an area where there is enough fat to pinch, usually the abdomen, thighs, or the back of the arms
Researchers from the Mayo Clinic and Yale School of Medicine published a study in JAMA Otolaryngology Head Neck Surgery on January 23, which found that the increase in thyroid cancer diagnosis linked to glucagon-like peptide-1 (GLP-1) receptor agonists disappeared after the first year of treatment, when compared to other diabetes medications
Patients report enhanced energy, mental clarity, improved sleep, and overall wellness improvements
Researchers are responsible for complying with all institutional safety policies and applicable local regulations